




PHARMACEUTICAL 2023

ALNYLAM PHARMACEUTICALS INC.
Rank 335 of 446





RealRate

PHARMACEUTICAL 2023

ALNYLAM PHARMACEUTICALS INC. Rank 335 of 446

Alnylam@20

The relative strengths and weaknesses of ALNYLAM PHARMACEUTICALS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ALNYLAM PHARMACEUTICALS INC. compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 34% points. The greatest weakness of ALNYLAM PHARMACEUTICALS INC. is the variable Other Liabilities, reducing the Economic Capital Ratio by 103% points.

The company's Economic Capital Ratio, given in the ranking table, is -39%, being 82% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	2,692,247
Cost of Goods Sold	140,174
Intangible Assets	0
Liabilities, Current	767,915
Liabilities, Non-Current	667,710
Other Assets	330,618
Other Compr. Net Income	-11,395
Other Expenses	32,806
Other Liabilities	2,268,957
Other Net Income	-341,921
Other Revenues	1,037,418
Property and Equipment	523,494
Research and Development	883,015
Selling, General and Administrative Expense	770,658

Output Variable	Value in 1000 USD
Assets	3,546,359
Liabilities	3,704,582
Expenses	1,826,653
Revenues	1,037,418
Stockholders Equity	-158,223
Net Income	-1,131,156
Comprehensive Net Income	-1,136,854
Economic Capital Ratio	-39%